$NBP Cashflow Statement | Understand Stock

$NBP

$1.26 +$0.01 (0.4%) Close

$NBP Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of CNY, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Less: net gain (loss) from discontinued operations
Net loss from continuing operations
Adjustments to reconcile net loss to net cash used in operating activities from continuing operations
Share-based compensation
Amortization of right-of use assets and interest of lease liabilities
Change in fair value and extinguishment of put right liabilities
Equity in loss of affiliates
Depreciation of property, equipment and software
Amortization of intangible assets
Impairment of goodwill
Settlement of TJ Biopharma repurchase obligations
Amortization of right-of use assets
Impairment of fixed assets
Impairment of assets held for sale
(Gain) loss on disposal of property and equipment
Fair value change of warrants
Fair value change of put right liabilities
Recognition of deferred cost for planned dual listing
Loss on deconsolidation of a subsidiary
Change in fair value of short-term and other investments
Fair value of acquired IPR&D asset expensed to R&D costs, net cash paid
Recognition of accumulated gain associated with available for sale debt securities
Change in fair value of equity securities
Changes in operating assets and liabilities
Prepayments and other receivables
Inventories
Accruals and other payables
Contract liabilities
Other non-current liabilities
Deferred subsidy income
Lease liabilities

Net cash used in operating activities
Operating lease liability, net
Accounts receivable
Contract assets

Net cash used in operating activities from continuing operations
Cash flows from investing activities
Proceeds from disposal of short-term and other investments
Purchase of short-term and other investments
Cash received from deconsolidation of a subsidiary

Net cash generated from (used in) investing activities
Purchase of short-term and other investments
Purchase of available-for-sale debt securities
Purchase of property, equipment and software
Proceeds from disposal of property and equipment
Capital injection in an affiliate
Proceeds from disposal of short-term investments
Net cash generated from (used in) investing activities from continuing operations
Cash flows from financing activities
Proceeds from initial public offering and over-allotment, net of underwriting discounts and commissions
Payments of the issuance cost in relation to private placement
Payments of cost in relation to planned dual listing
Proceeds from exercise of warrants
Proceeds from underwritten offering, net
Payments of deferred offering costs
Payment for stock repurchases
Prepayment for stock repurchase
Cash received from collection of prepayment for stock repurchase program
Net cash generated from financing activities
Proceeds from exercise of stock options
Proceeds from issuance of ordinary shares for restricted share units
Proceeds from bank borrowings
Repayment of bank borrowings
Net cash generated from (used in) financing activities from continuing operations

Discontinued operations:
Net cash used in operating activities
Net cash (used in) generated from investing activities
Net cash (used in) generated from financing activities
Net cash used in discontinued operations
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Additional ASC 842 supplemental disclosures
Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities
Right-of-use assets obtained in exchange for operating lease obligations
Other supplemental cash flow disclosures
Income tax paid
Interest paid
Non-cash activities
Payables for purchase of property, equipment and software
Accrued planned dual listing costs payable
Recognition of put right liabilities
Accrued acquisition costs and deferred payments associated with Bridge Health acquisition
Unrealized gain/(loss) on available-for-sale debt securities
Cash and cash equivalents
Restricted cash
Cash and cash equivalents in current assets of discontinued operations
Restricted cash in non-current assets of discontinued operations

Comments